In This Article:
-
Catalent Inc (NYSE: CTLT) agreed to acquire Metrics Contract Services, a full-service specialty Contract Development and Manufacturing Organization, for $475 million from Mayne Pharma Group Limited.
-
Upon completion, the acquisition will strengthen Catalent's integrated oral solid formulation development, manufacturing, and packaging capabilities.
-
The deal will also expand Catalent's capacity to handle highly potent compounds.
-
Metrics Contract operates a 333,000-square-foot facility in Greenville, North Carolina. It includes 16 manufacturing suites, with 11 designed to handle highly potent compounds and two packaging lines.
-
The facility's estimated annual production capacity exceeds one billion oral solid dose units.
-
The acquisition is expected to close before the end of 2022, and a team of over 400 employees will join Catalent.
-
Mayne Pharma and Catalent have also agreed on a long-term supply agreement whereby the Greenville facility will continue manufacturing multiple Mayne Pharma products.
-
Catalent held cash & cash equivalents of $786 million at the end of the March quarter.
-
Price Action: CTLT shares closed at $108.13 on Tuesday.
See more from Benzinga
-
SAB Biotherapeutics Shifts Focus On Infection Candidate As DoD Contract Closes
-
Halozyme Therapeutics Shares Jump On Better Than Expected Annual Guidance
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.